← All trials
NCT07309614
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Jan 31, 2029
- Completion date
- Jan 31, 2030
- First posted
- Dec 30, 2025
- Last posted
- Dec 30, 2025
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of SherbrookeLead sponsor
- Government of CanadaCollaborator
- RegeneronCollaborator
- SanofiCollaborator
- University of Western AustraliaCollaborator
- University of OxfordCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.